148 related articles for article (PubMed ID: 31343342)
1. Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis.
Rubin J; Teruya S; Helmke S; De Los Santos J; Alvarez J; Maurer MS
Amyloid; 2019; 26(sup1):4-5. PubMed ID: 31343342
[No Abstract] [Full Text] [Related]
2. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Gertz MA; Benson MD; Dyck PJ; Grogan M; Coelho T; Cruz M; Berk JL; Plante-Bordeneuve V; Schmidt HHJ; Merlini G
J Am Coll Cardiol; 2015 Dec; 66(21):2451-2466. PubMed ID: 26610878
[TBL] [Abstract][Full Text] [Related]
3. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.
Di Nora C; Sponga S; Ferrara V; Patriarca F; Fanin R; Nalli C; Lechiancole A; Vendramin I; Livi U
J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):261-267. PubMed ID: 33633041
[TBL] [Abstract][Full Text] [Related]
5. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
7. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
8. Misconceptions and Facts About Cardiac Amyloidosis.
Nguyen FD; Rodriguez M; Krittanawong C; Witteles R; Lenihan DJ
Am J Cardiol; 2021 Dec; 160():99-105. PubMed ID: 34610875
[TBL] [Abstract][Full Text] [Related]
9. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.
Papoutsidakis N; Miller EJ; Rodonski A; Jacoby D
J Card Fail; 2018 Feb; 24(2):131-133. PubMed ID: 29305186
[No Abstract] [Full Text] [Related]
10. Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors.
Barge-Caballero G; Vázquez-García R; Barge-Caballero E; Couto-Mallón D; Paniagua-Martín MJ; Barriales-Villa R; Piñón-Esteban P; Bouzas-Mosquera A; Pombo-Otero J; Debén-Ariznavarreta G; Vázquez-Rodríguez JM; Crespo-Leiro MG
Med Clin (Barc); 2021 Apr; 156(8):369-378. PubMed ID: 32591181
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
[No Abstract] [Full Text] [Related]
12. Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
Stein AP; Matthia EL; Petty SA; Stewart B; Vilaro JR; Al-Ani MAZ; Ahmed MM; Aranda JM; Hiemenz JW; Parker AM
Am J Cardiol; 2024 Jan; 210():85-92. PubMed ID: 37852567
[TBL] [Abstract][Full Text] [Related]
13. Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses.
Mori M; An Y; Katayama O; Kitagawa T; Sasaki Y; Onaka T; Yonezawa A; Murata K; Yokota T; Ando K; Imada K
Ann Hematol; 2015 Nov; 94(11):1885-90. PubMed ID: 26251157
[TBL] [Abstract][Full Text] [Related]
14. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Siontis GC; Windecker S
J Am Coll Cardiol; 2015 Jan; 65(3):313. PubMed ID: 25614435
[No Abstract] [Full Text] [Related]
15. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Kim WK; Rolf A; Möllmann H
J Am Coll Cardiol; 2015 Jan; 65(3):312-3. PubMed ID: 25614434
[No Abstract] [Full Text] [Related]
16. A representative case of hereditary transthyretin amyloidosis complicated by intramyocardial hemorrhage.
Yagi H; Amiya E; Shintani Y; Nitta D; Numakura S; Hosoya Y; Watanabe M; Fukayama M; Komuro I
Amyloid; 2015 Mar; 22(1):70-2. PubMed ID: 25427692
[No Abstract] [Full Text] [Related]
17. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Cardiac Amyloidosis.
Saito Y; Nakamura K; Ito H
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008444
[TBL] [Abstract][Full Text] [Related]
19. Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Di Bella G; Minutoli F
Amyloid; 2018 Jun; 25(2):135. PubMed ID: 29523040
[No Abstract] [Full Text] [Related]
20. Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Castaño A; Bokhari S; Maurer MS
J Am Coll Cardiol; 2015 Jan; 65(3):311-2. PubMed ID: 25614433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
